Freebase
The neutral chemical form. Its handling and dissolution characteristics differ from a salt form, and identity still depends on analysis.
Ibogaine tablets and other forms
Forms & Chemistry
A tablet, capsule, powder, extract, or plant material can look like a clear category. Chemically, those labels leave important questions unanswered.
Start with the distinction
Presentation is not standardization.
“Tablet” and “capsule” describe how material is presented. They do not, by themselves, establish what compound is present, how much is present, whether a batch is consistent, or whether manufacturing controls were used. A pressed tablet may contain a purified salt, a botanical powder, a mixed extract, fillers, or some combination of these.
Ibogaine is an indole alkaloid associated with Tabernanthe iboga; a concise chemical overview is available through the ibogaine reference entry. For the wider foundation on terminology and uncertainty, the main Lanternfold guide frames why product language should be read cautiously.
Hydrochloride salt
A salt made by pairing ibogaine with hydrochloric acid. “HCl” identifies a form, not a verified purity or finished-product standard.
Plant or extract
Root-bark powders and total alkaloid extracts can contain multiple naturally occurring iboga alkaloids in variable proportions.
Chemical forms and processing
What the form can—and cannot—tell you.
Freebase ibogaine refers to the unprotonated compound. Hydrochloride is a salt form produced when the compound is reacted with hydrochloric acid. In principle, salt formation can affect practical properties such as solubility and handling. It does not remove the need to establish identity, composition, contaminants, or batch consistency.
Root-bark powder is plant material rather than isolated ibogaine. A “total alkaloid” extract generally signals a mixture of alkaloids recovered from botanical material, not a single purified compound. That distinction matters because the proportions of ibogaine and other iboga alkaloids can vary by source material and processing.
- Freebase and hydrochloride identify chemical state, not product quality.
- Powders and mixed extracts may retain a broader alkaloid profile.
- Capsules and tablets can conceal meaningful differences in underlying material.
“A finished dosage shape is evidence of presentation—not proof of composition.”
Labels can use terms such as “microdose,” “extract,” “HCl,” or “standardized” without making the analytical record visible. A careful reading separates the seller’s description from evidence about what a particular batch contains.
Markers, stability, variability
Analytical questions come before product claims.
Common laboratory approaches can include chromatographic methods used to separate and identify compounds, with mass spectrometry sometimes used to help characterize them. These methods can address different questions: whether ibogaine is present, an estimated concentration, and whether other alkaloids or unexpected compounds appear in a sample. A label alone cannot answer all of those questions.
Solubility and stability are also formulation questions. Chemical form, moisture, light, heat, excipients, packaging, and storage can affect a material’s condition over time. The FDA’s drug safety information underscores why product identity and safety are not interchangeable concepts, especially where a product has not gone through a regulated approval pathway.
For a broader description of how Lanternfold approaches evidence, uncertainty, and source context, see the organization’s stated approach. This page does not offer dosing, treatment, or purchasing guidance.
Regulation and labels
Marketed language does not settle legal status.
Words such as “supplement,” “research,” or “microdose” are marketing descriptors, not a universal legal classification. Laws and enforcement practices differ by jurisdiction, and the legal status of ibogaine should not be inferred from packaging, availability, or a product’s claimed purpose.
In the United States, ibogaine is listed in Schedule I under the federal controlled-substances framework; the DEA’s explanation of drug scheduling provides the general federal structure. Regulatory classification is separate from chemical identity and separate again from the questions raised by a particular formulation.
Because variability can matter, form-specific questions belong alongside the safety issues described in the cardiac-risk context. No format—tablet, capsule, extract, powder, or plant material—makes those questions disappear.
Plain answers
Frequently asked questions
Does a tablet mean a product is standardized?
No. Tablet and capsule describe physical presentation, not verified identity, concentration, purity, or manufacturing controls. Documentation and independent analysis are distinct questions.
Is total alkaloid extract the same as purified ibogaine?
No. A total alkaloid extract generally refers to a mixture recovered from plant material. Its profile may include ibogaine and other iboga alkaloids, with proportions that can vary.
What does “microdose” establish?
It is a marketed descriptor, not a reliable statement of chemical content, legal status, safety, or a standardized amount. It should not be treated as an analytical result.
Why do formulation details matter?
Chemical form, source material, processing, excipients, packaging, and storage can all affect how a product is described and how consistent one unit may be with another.
Keep the questions separate.
Chemical form, physical presentation, analytical evidence, legal classification, and safety are related—but they are not interchangeable.